PM360

APRIL 22, 2024

In the swiftly changing realm of advanced therapies like biosimilars, rare disease molecules, and cell and gene therapies, a strong scientific interpretation and orientation is essential. Gone are the days when Medical Affairs merely acted as a liaison between pharmaceutical companies and healthcare professionals (HCPs).

Medical 52

Medical Healthcare Healthcare Education 52

PM360

SEPTEMBER 7, 2023

Mason learned that lesson while working with argenx to launch VYVGART (efgartigimod alfa-fcab), the first FDA-approved treatment of its kind for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG), a rare autoimmune neuromuscular disease. We also put big pull tags on the little pouches that held the items.

Patients 105

Patients Pharma Education Doctors 105

PM360

APRIL 7, 2023

The shift toward longer, more adequate timeframes to establish proof of concept can be as long as three to four years, 1 given the complex requirements for developing and launching specialty drugs and cell and gene therapies (CGTs) for individuals with complex conditions or rare or orphan diseases.

Manufacturing 52

Manufacturing Marketing Patients Safety 52

Pharmaceutical Technology

JANUARY 27, 2023

On January 18, Sanofi launched a new warranty program for its rare blood disorder drug Cablivi (caplacizumab), which tackles value-based agreements in a slightly different way. A refund up to 12 inpatient doses will also be offered for patients whose disease worsens while receiving treatment.

Patients 52

Patients Pharmaceutical Manufacturing Healthcare Provider 52